US: BRIBF - Brii Biosciences Limited

Altı ay boyunca karlılık: +142.39%
Temettü getirisi: 0.00%

Promosyon programı Brii Biosciences Limited

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Brii Biosciences Limited

Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV.

daha fazla ayrıntı
It develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета cny
Сайт https://www.briibio.com
Цена ао 0.302
Günlük fiyat değişimi: 0% (0.3042)
Haftalık fiyat değişimi: 0% (0.3042)
Aylık fiyat değişimi: +0.7285% (0.302)
3 ayda fiyat değişimi: +142.39% (0.1255)
Altı ayda fiyat değişimi: +142.39% (0.1255)
Yıllık fiyat değişimi: +32.32% (0.2299)
3 yılda fiyat değişimi: -86.05% (2.18)
Yılbaşından bu yana fiyat değişimi: +142.39% (0.1255)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Toplam: 2.5

Yeterlik

İsim Anlam Seviye
ROA, % 0 0
ROE, % 0 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA 0 10
Toplam: 10

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % -78.73 0
karlılık Ebitda, % -67.51 0
karlılık EPS, % -95.34 0
Toplam: 2
Daha fazla ayrıntı

Süpervizör İş unvanı Ödeme Doğum yılı
Dr. Zhi Hong Ph.D. Co-founder, Executive Chairman of the Board & CEO 1964 (61 yıl)
Dr. Ankang Li C.F.A., J.D., Ph.D. Chief Financial & Strategy Officer, Company Secretary and Executive Director 1979 (46 yıllar)
Dr. Eleanor de Groot Ph.D. Chief Technology Officer 1969 (56 yıllar)
Dr. Brian Alvin Johns Ph.D. Chief Scientific Officer
Sarah Qiu Associate Director of Investor Relations
Ms. Karen Del Barrio Neuendorff Chief People Officer & Head of Human Resources 1976 (49 yıllar)
Mr. Coy Stout Head of Patient Advocacy 1972 (53 yıl)
Dr. Lianhong Xu Ph.D. Head of Discovery 1967 (58 yıllar)
Dr. Qing Zhu Ph.D. Head of China Research & Development 1968 (57 yıllar)
Dr. David Margolis M.D., M.P.H. Chief Medical Officer 1975 (50 yıllar)

Adres: China, Beijing, Building 7 International Science Park - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.briibio.com